CLARITY AD
E125383
CLARITY AD is a pivotal phase 3 clinical trial that evaluated the efficacy and safety of the anti-amyloid Alzheimer’s disease drug lecanemab (Leqembi) in patients with early Alzheimer’s disease.
All labels observed (1)
| Label | Occurrences |
|---|---|
| CLARITY AD canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1103715 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CLARITY AD Context triple: [Leqembi, hasKeyClinicalTrial, CLARITY AD]
-
A.
.ad
.ad is the country code top-level domain (ccTLD) assigned to the Principality of Andorra for use in internet addresses.
-
B.
AD
AD is a CERN facility that slows down antiprotons so they can be used in precision experiments studying antimatter.
-
C.
ADS
ADS is the stock ticker symbol under which the global sportswear company Adidas is traded on the Frankfurt Stock Exchange.
-
D.
DART for Advertisers
DART for Advertisers is an online ad-serving and campaign management platform that enabled advertisers to create, target, deliver, and track digital advertising across websites.
-
E.
FCB
FCB is the abbreviation commonly used for the Cuban Baseball Federation, the governing body for organized baseball in Cuba.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: CLARITY AD Target entity description: CLARITY AD is a pivotal phase 3 clinical trial that evaluated the efficacy and safety of the anti-amyloid Alzheimer’s disease drug lecanemab (Leqembi) in patients with early Alzheimer’s disease.
-
A.
.ad
.ad is the country code top-level domain (ccTLD) assigned to the Principality of Andorra for use in internet addresses.
-
B.
AD
AD is a CERN facility that slows down antiprotons so they can be used in precision experiments studying antimatter.
-
C.
ADS
ADS is the stock ticker symbol under which the global sportswear company Adidas is traded on the Frankfurt Stock Exchange.
-
D.
DART for Advertisers
DART for Advertisers is an online ad-serving and campaign management platform that enabled advertisers to create, target, deliver, and track digital advertising across websites.
-
E.
FCB
FCB is the abbreviation commonly used for the Cuban Baseball Federation, the governing body for organized baseball in Cuba.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
Alzheimer’s disease clinical trial
ⓘ
phase 3 clinical trial ⓘ |
| allocation | parallel assignment ⓘ |
| blinding | double-blind ⓘ |
| coDevelopment | Eisai and Biogen ⓘ |
| conditionStudied |
Alzheimer’s disease
ⓘ
linked to:
Alzheimer's disease
|
| controlGroup | placebo-treated participants ⓘ |
| controlType | placebo ⓘ |
| coSponsor | Biogen ⓘ |
| design |
double-blind
ⓘ
placebo-controlled ⓘ randomized ⓘ |
| drugBrandName | Leqembi ⓘ |
| drugClass | disease-modifying therapy for Alzheimer’s disease ⓘ |
| drugGenericName |
lecanemab
ⓘ
linked to:
Leqembi
|
| drugMechanism | anti-amyloid monoclonal antibody ⓘ |
| drugTarget | aggregated amyloid beta ⓘ |
| evaluatesDrug |
Leqembi
ⓘ
lecanemab ⓘ
linked to:
Leqembi
|
| experimentalGroup | lecanemab-treated participants ⓘ |
| geographicScope | multinational ⓘ |
| indication |
early Alzheimer’s disease
ⓘ
mild Alzheimer’s disease dementia ⓘ mild cognitive impairment due to Alzheimer’s disease ⓘ |
| interventionType | intravenous lecanemab ⓘ |
| phase | Phase 3 ⓘ |
| population | patients with early symptomatic Alzheimer’s disease ⓘ |
| populationRequirement | evidence of brain amyloid pathology ⓘ |
| primaryEndpointType |
clinical efficacy
ⓘ
cognitive and functional outcomes ⓘ |
| primaryObjective | evaluate efficacy of lecanemab in early Alzheimer’s disease ⓘ |
| relatedRegulatoryOutcome |
support for FDA approval of lecanemab
ⓘ
support for regulatory submissions for Leqembi ⓘ |
| safetyEndpointType |
adverse events
ⓘ
amyloid-related imaging abnormalities ⓘ |
| safetyFocus |
monitoring of ARIA-E
ⓘ
monitoring of ARIA-H ⓘ |
| secondaryObjective | evaluate safety of lecanemab in early Alzheimer’s disease ⓘ |
| sponsor | Eisai ⓘ |
| sponsorCountry |
Japan
ⓘ
United States ⓘ
linked to:
United States of America
|
| sponsorRole | Eisai as lead sponsor ⓘ |
| targetPathology | amyloid beta ⓘ |
| therapeuticArea |
neurodegenerative disease
ⓘ
neurology ⓘ |
| trialRoleInField | pivotal evidence for anti-amyloid therapy in early Alzheimer’s disease ⓘ |
| trialType | interventional ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: CLARITY AD Description of subject: CLARITY AD is a pivotal phase 3 clinical trial that evaluated the efficacy and safety of the anti-amyloid Alzheimer’s disease drug lecanemab (Leqembi) in patients with early Alzheimer’s disease.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.